Tried and True Tips. Common BG Patterns & Fixes 11/2/16. Tried and True Tips and New Advances in Diabetes. The Right Number of Carbs for a Low

Similar documents
Paradigm/Guardian CGM Screens. CareLink Online Reports. Make Your Own Jackson Pollack. CGM by Jackson Pollack. How To Read CGM Screens/Reports

The Latest on Insulin Pumps

Terms. Glucose Management. Many Thanks. Disclosure. What We ll Cover. T o. Medtronic of Canada Ltd., Sarrah Morris, BScN, RN, MBA,

Diabetes Technology Update. Sarah Konigsberg, MD Diabetes & Endocrine Assoc. April 7, 2018

DIABETES TECHNOLOGY: WHERE ARE WE NOW AND WHERE ARE WE GOING? Presented by: Tom Brobson

Insulin Pumps and Continuous Glucose Sensors- Embracing Technology. Susan Cavalier, BS, RN, CDE Manager, Diabetes Educator Sanford Diabetes Education

CGM and Closing The Loop

10:20 AM March 5, B 100% 235 u. 124 mg/dl 3 HRS INSULIN ON BOARD:

NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP

Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier?

Diabetes and Technology. Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE

Making the Most of Continuous Glucose Monitoring

Technology in Diabetes Management Irl B. Hirsch, MD University of Washington

JDRF RESEARCH UPDATE. Daniel Finan, Ph.D. Research Director

DIABETES TECHNOLOGY: ENDLESS CHOICES FOR HEALTHY MANAGEMENT

OBJECTIVES THE PAST INNOVATIVE TECHNOLOGY & DIABETES DIABETES MIS MANAGEMENT IMPROVEMENTS IN DIABETES MANAGEMENT

RELEASED. first steps. Icon Icon name What it means

Today s Goals 10/6/2017. New Frontiers in Diabetes Technology. Disclosures

More Than 1 Year of Hybrid Closed Loop in Pediatrics. Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center

Predicts and helps prevent lows with. zero fingersticks NOW FEATURING BASAL-IQ TECHNOLOGY

5/16/2018. Integrating Diabetes Technology Into your Practice : Insulin Pump Therapy. Diosclosures. What exactly is an Insulin Pump?

Future Direction of Artificial Pancreas. Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida

Update on Diabetes Technology

Advanced Pump Workshop

What is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming

Disclosure. Karmeen Kulkarni, MS,RD, BC-ADM, CDE. Employed by Abbott Diabetes Care, a division of Abbott Laboratories

Getting Started. Learning Guide. with Insulin Pump Therapy. PUMP Foundations. for the MiniMed 530G with Enlite

USING THE MINIMED 670G SYSTEM. Instructions for the Experienced MiniMed 630G System User

The Realities of Technology in Type 1 Diabetes

Abbott FreeStyle Libre Pro System

Insulin Pump Therapy. WakeMed Children s Endocrinology & Diabetes WakeMed Health & Hospitals Version 1.3, rev 5/21/13 MP

Dexcom Current and Future Technology Innovations. Jorge Valdes Chief Technical Officer

Technology in Diabetes Care: Emerging Level

UNDERSTANDING THE BASIC FEATURES AND MANAGEMENT IN THE SCHOOL SETTING CHRISTINE HERTLER RN BSN CDE & MARY MCCARTHY RN CDE

USING THE MINIMED 670G SYSTEM

Pumps & Sensors made easy. OPADA ALZOHAILI MD FACE Endocrinology Assistant Professor Wayne State University

Report Reference Guide. THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1

Pumping Insulin is it for your patients?

Getting you up to speed Quick Reference Guide

The next five years in diabetes technology: closed-loop systems

Emerging Automated Insulin Delivery Systems

MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps

WHEN YOUR PANCREAS IS NOT A HAPPY CAMPER A PRESENTATION ON DIABETES MANAGEMENT IN THE CAMP SETTING AMANDA COSCHI, BSCN, RN, CDE

The pump that gets updated, not outdated. *

MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps

Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)

Dr Sander Zwart MD, FACP, ECNU Arizona-AACE 2016 Annual Meeting

Performance-powered. The OneTouch. Ping insulin pump and meter-remote.

Hybrid Closed Loop Status & Practical Challenges in Implementation

Company Overview February 26, 2019

Objectives. Glucose Monitoring Today. Tracking Glucose ISO Standards. Continuous Glucose Monitoring & Diabetes Management 3/7/2015

The Growing Future of Diabetes: Insulin Pump Therapy in Type 1 and 2 Diabetes

When Will CGM Replace SMBG? Roy W. Beck, MD, PhD. JAEB Center for Health Research Tampa, Florida

Advances in Diabetes Care Technologies

Abbott FreeStyle Libre Pro System

1 Dexcom G4 Platinum User Guide May 2012

Diabetes Technology in Irl B. Hirsch, MD University of Washington School of Medicine Seattle, WA

Ambulatory Artificial Pancreas Platform (AAPP) User Manual

Updates in Diabetes Technology

MEDICAL POLICY Continuous Glucose Monitoring Systems and Insulin Pumps

Approved by: Integrated Health Quality Management Subcommittee Effective Date: Department of Origin: Integrated Healthcare Services.

Pump and Sensor Data Interpretation. Irl B. Hirsch, MD University of Washington School of Medicine

Insulin Pump Therapy in children. Prof. Abdulmoein Al-Agha, FRCPCH(UK)

PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS)

BASICS OF INSULIN PUMPS. Jennifer Okemah MS RD BCADM CDE CSSD

Advances in Diabetes Care Technologies

Animas Vibe System World-class insulin pumping meets world-class CGM*

People with type 1 diabetes and Do It Yourself (DIY) technology solutions ABOUT THIS POSITION STATEMENT

PATIENT TRAINING CHECKLIST MINIMED 670G SYSTEM

Diabetes through my eyes. Rick Mauseth, M.D. W.A.D.E. April 2013

Why (and how) I built an artificial

DIABETES & ENDOCRINE DIABETES TECHNOLOGY: HOW TO STAY CURRENT WITH ONGOING TECHNOLOGY ADVANCEMENT

Diabetes Devices Workshop Angela Aldrich, PharmD, PhC April Mott, PharmD, PhC, BCPS Presbyterian Medical Group 28 January 2018

Optimizing Therapy and Clinical Outcomes Using Real-Time Continuous Glucose Monitoring (AADE PRODUCT THEATRE) August 7, 2014 Orlando, FL

Report Reference Guide

THE MINIMED 670G SYSTEM SCHOOL NURSE GUIDE

Advances Towards the Bionic Pancreas.

Comparative table of insulin pumps

Continuous Glucose Monitoring (CGM) Dexcom G6 Training for Healthcare Professionals and Patients

The Artificial Pancreas

Diabetes Management: Current High Tech Innovations

CareLink. software REPORT REFERENCE GUIDE. Management Software for Diabetes

Designed with your patients lives in mind

THERAPY MANAGEMENT SOFTWARE FOR DIABETES

7/18/2017. Everything discussed in this presentation is off-label. (And that s ok.) Dana Lewis Founder, #OpenAPS WARNING: Disclosure to Participants

Advances in Diabetes Care Technologies

Advances in Diabetes Technology Part II: Analysis of Diabetes Self Management Devices and Support Tools

ADVANCES IN DIABETES TECHNOLOGY: A FOCUS ON CONTINUOUS GLUCOSE MONITORING 9:15 10:15 AM

Newer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference

Continuous Glucose Monitoring (CGM)

Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim

How to Transfer Your Settings

COMPANY OVERVIEW. July 30, 2018

1. Continuous Glucose Monitoring

INSPIRED BY GIVE HER MORE. The MiniMed 670G system is the world s first insulin delivery system that automatically adapts to your child s needs.

Welcome to CareLink Pro

COMPANY OVERVIEW. April 26, 2018

Artificial Pancreas Technologies: New Tools to Improve Diabetes Care Today and Tomorrow

A Novel Adaptive Basal Therapy Based on the Value and Rate of Change of Blood Glucose

MINIMED 640G SYSTEM^ Getting Started WITH CONTINUOUS GLUCOSE MONITORING

Transcription:

Tried and True Tips and New Advances in Diabetes San Diego Pump Club, Oct 1, 216 John Walsh PA, CDTC Tried and True Tips How Basal Rate Change Affects BG 1.7 Total Units When You Change a Basal Rate When you change a basal rate, it helps to know how many total units the change brings. Change in Basal Rate Total units over 6 hrs Total units over 8 hrs Total units over 24 hrs +/-.25 u/hr +/-.15 u +/-.2 u +/-.6 u +/-.5 u/hr.3 u.4 u 1.2 u +/-.1 u/hr.6 u.8 u 2.4 u Basal adjustments of.25 and.1 u/hr equal.6 and 2.4 units over the entire day. For a glucose that falls or rises slightly during a basal test, a basal change of.25 or.5 u/hr (or.2 and.4 units over 8 hours) may fix this. Avg. rise or fall in BG/hr = Change in Basal X CorrF Example: +/-.5 x 4 mg/dl/unit = 2 mg/dl average rise or fall in BG per hour Plus a small additive effect over longer time periods 3 G 25 L U 2 C 15 O S 1 E 8 5 mg/dl Common BG Patterns & Fixes BGs: F E 2 am 4 am 6 am 8 am B2 B1 C1 1 am noon 2 pm 4 pm 6 pm 8 pm 1 pm midnight 2 am 4 am 6 am 8 am 1 am A) most common pattern (raise afternoon & evening basal, lower supper CarbF), B) frequent lows (lower TDD by 5-1% & find new settings), C) high and flat most of the time (raise basal rates), D) frequent highs with post-meal rise (raise basal rates & lower CarbF/ICR), E) highs or lows at particular times of the day (raise or lower prior basal rate or CarbF in previous meal), F) post-meal spiking (bolus earlier, lower CarbF), G) over-correction of highs (do not increase recommended bolus, raise the CorrF/ISF, set DIA to 4.5 hrs or longer), H) over-treatment of lows (stop lows, don t overtreat). Several patterns often coexist. Adjust basals or boluses most responsible. C2 D G A H 17. 14. 11. 8. 5.5 4. 3. mmol/l The Right Number of Carbs for a Low Glucose Levels Before and After Infusion Set Changes Treat lows with: Grams of carb = Wt(lbs)/1 + (BOB* x CarbF) 2 19 Average Glucose: 6-Hour Intervals Example: Amy s BG = 52 mg/dl with 2u of BOB (CarbF = 1 g/u)! At 12 lbs, she needs 12 grams for the low glucose! Plus 2u BOB x 1 gram/u = 2 grams to cover her BOB! Amy needs 12 g + 2 g = 32 grams for this low * DIA time must be accurate Don t shorten DIA to fix control problems! 18 Set 17 Change 16 15 1 1 2 3 4 5 6 Day 7-24Hr 6Hr 3Hr 54Hr 78Hr 12Hr 126Hr 15Hr Average glucose levels for 6-hour intervals before and after infusion set change in 396 pumps (>2 set changes/pump). Walsh J, Roberts R, Bailey T. Unpublished data from the Actual Pump Practices study. 1

Can We Extend Infusion Set Use? BD Flowsmart for Silent Occlusions 5 4 3 Number of Infusion Sets in Use Per Day BD researchers suspected infusion pressure might increase with a new intradermal sets, but not with standard sets Silent occlusions were seen in both 2 Set Change 1 Day 1 +1 +2 3 4 5 6 7-24Hr 6Hr 3Hr 54Hr 78Hr 12Hr 126Hr 15Hr Most pump wearers use an infusion set for 2-3 days Walsh J, Roberts R, Bailey T. Unpublished data from the Actual Pump Practices study. Silent occlusions lasting >3 min. were more common during first 4 hours of set use FlowSmart dual port set may eliminate some unexplained hypoglycemia Pettis RJ, Hirsch L, Kapitza C, et al. Diabetes Technol Ther. 211;13:443-45. Steel versus Teflon Sets Safe Site Setup Steel: No kinking Fewer silent occlusions 1 Manual insertion Less failure Better biocompatibility, less back pressure 2 Easier to train 28-3 gauge Teflon: More selections Straight or slanted Manual or automatic insertion Less needle phobia 25 gauge (27-gauge introducer needle) FlowSmart: 28 gauge (3- gauge introducer Steel sets have a flatter profile and can be secured as shown. Alternate setup would be to place IV3 or Tegaderm adhesive over needle and line, and remove adhesive from connector to let it dangle. 1 McVey E, Keith S, Herr J, Sutter D, Pettis R. J Diabetes Sci Technol. 215. In press. 2 Højbjerre L, Skov-Jensen C, Kaastrup P, et al. Diabetes Technol Ther. 29;11:31-36. Super Bolus = Faster Action Unwanted meal spike Gone with a Super Bolus Use temp basal reduction to shift part of the next 2 to 3.5 hrs of basal insulin into a bolus Better readings and low risk of lows. 1,2 Done by user, not the pump 1 J. Walsh: http://www.diabetesnet.com/diabetes_presentations/ s uper-bolus.html September, 24 2 J. Bondia, E. Dassau, H. Zisser, R. Calm. J. Vehí, L. Jovanovic, F.J. Doyle III, Coordinated basalbolus for tighter postprandial glucose control in insulin pump therapy. JDST, 3(1), 89-97, 28 Will Hypoglycemia Soon Disappear? Hypo-Minimizer pumps (now available) CGMs can predict BG (hypo or hyper events) 3 min. ahead (but don t yet inform wearers) Soon-to-arrive insulins peak faster and don t stick around as long: FIAsp and Biochaperone lispro Hypo-Manager software that recommends a bolus or the exact carbs needed for each glucose 2

A Thing of the Past? Trendline vs Trend Arrow and BOB 79 mg/dl (4.4 mmol/l) with down arrow and trend line 79 mg/dl with down arrow and BOB A CGM screen with BOB gives more information!!! Should Predicted BG Replace Trend Arrow? New Faster Insulin Aspart (FIAsp) 3 Recommended dose adjustments vs actual adjustments in survey of 222 pumpers for a 22 mg/dl glucose WIDE VARIATION in individual adjustments Trend arrows are imprecise and a poor guide for dosing A 3 min predicted BG would be a far better guide Pettus J, Price DA, Edelman SV. Endocr Pract. 215 Jun;21(6):613-2. New insulin is slightly faster than Novolog with avg BG 13 mg/dl lower at 1 hr, 22 mg/dl lower at 2 hrs, with A1c reduction of.15%. New Biochaperone-lispro Remote Software Upgrades Biochaperone-lispro A protein molecule is added to lispro (Humalog), to speed up insulin action. Tandem t:slim X2 received FDA approval to upgrade software remotely, similar to phones and PCs. Lets existing hardware be rapidly upgraded for artificial pancreas and other features. Get a new pump in seconds, not years! Available Oct, 216 www.tandemdiabetes.com 3

Connectivity the Next Big Wave Bluetooth LE connects to: Pumps, smart insulin pens, meters, CGMs activity monitors (FitBit, JawBone, MotoActv, BodyMedia) Cell phones Integrates data from different devices Tidepool, Glooko, MySugr DiaSend Telecommunication companies and the FDA are on board! BLE-4 range = 15 ft BLE-5 range = 5 ft Bolus Calculators BCs How Many and How Good? A review of 42 BC apps that existed in 214 showed that only one fulfilled all the desired criteria and less than one third showed how they calculated a bolus recommendation Only 8 BCs are FDA approved in insulin pumps (5), BG meters (2), and a Bluetooth insulin pen Today, over 84 BC apps exist Analysis of 42 Phone Apps The majority of insulin dose calculator apps provide no protection against, and may actively contribute to, incorrect or inappropriate recommendations that put current users at risk of both catastrophic overdose and more subtle harms resulting from suboptimal glucose control. 1 It is time to standardize BCs for safety. 1. Huckvale, K., Adomaviciute, S., Prieto, J. T., Leow, M. K. S., & Car, J. (215). Smartphone apps for calculating insulin dose: a systematic assessment. BMC Medicine, 13(1). Pump Settings Often Wrong 1,2 Bolus Calculator Settings Number of Pumps 8 7 6 5 4 3 2 1 CarbF settings found in pumps 5 7 Carb Factors Found In 45 Pumps 1 115 1 2 R² =.43 15 2 1 2 3 4 5 6 7 8 9 1 11 12 13 14 15 16 17 18 19 2 21 22 Carb Factor R 2 =.43 34 of 45 pumps (8.4%) had no carb factor Don t use magic numbers! Only 4% of CarbFs in 45 pumps had an expected value People prefer magic numbers 5, 1, 15, and 2 g/unit. Formulas provide accurate settings > far better than WAG! 1. J Walsh, R Roberts, T Bailey: J Diab Science & Technology 21, Vol 4, #5, Sept 21 2. J. Walsh, D. Wroblewski, and TS Bailey: Insulin Pump Settings A Major Source For Insulin Dose Errors, Diabetes Technology Meeting 27 4

Case Study Decision Support Software Decision Support for Settings JD is a 2 yo DM1 college student referred to clinic. Wt 18 lb (84 kg), TDD = 8 u, avg BG = 194 mg/dl (1.8 mmol/l). Basal rate: 1.8 u/hr CarbF CorrF DIA 1 gr 45 mg/dl (2.5 mmol/l) 4 hrs A1c 8.4% www.opensourcediabetes.org Results of Decision Support Suggestions JD s Pump Settings: Original New TDD 8 u 85 u Basal rate: 1.8 u/hr 1.7 u/hr CarbF 1 5.6 CorrF 45 24 DIA 4 hrs 5 hrs A1c 8.4% 6.9% CGM Advances www.opensourcediabetes.org DIAMOND Study Do CGMs Work? HbA1c Treatment Group Differences Randomized Trial of 158 adult MDI users with T1D Randomly assigned to CGM (Dexcom G4 Platinum CGM System with software 55) or Usual Care Mean baseline HbA1c 8.6% in both groups Primary outcome HbA1c at 24 weeks completed by 98% CGM usage in month 6: >6 days/wk in 93% Results CGM: Reduced HbA1c by.6% compared with control group consistent reduction in sub-groups: baseline HbA1c, age, education Increased Time-in-Range Reduced Biochemical Hypoglycemia Reduced Glycemic Variability Mean HbA1c, % 8.8 8.6 8.4 8.2 8. 7.8 7.6 7.4 7.2 8.6% 8.6% 7. Baseline Adjusted mean difference (95% CI) P<.1 7.6% 8.1% Week 12 -.5% (-.7% to -.3%) P<.1 7.7% 8.2% Week 24 -.6% (-.8% to -.3%) CGM Usual care 5

HbA1c Secondary Outcomes Week 24 Percentage of Time Glucose Levels <6 mg/dl % of Subjects 6 5 4 3 2 1 P=.2 18% 4% P<.1 38% 11% P<.1 P<.1 52% 52% 19% HbA1c <7.% HbA1c <7.5% HbA1c Reduction of 1% 21% CGM Usual care HbA1c <7.% or Reduction of 1% Time <6 mg/dl, % Daytime (6 AM to 1 PM) P=.2 4.5 4. 3.5 3. 2.5 2. 1.7% 1.6% 1.6% 1.5 1..9%.5. Baseline Week 24 Time <6 mg/dl, % Nighttime (1 PM to 6 AM) P=.5 4.5 4.% CGM 4. 3.5 2.9% 3. 2.4% 2.5 2. 1.5 1..6%.5. Baseline Week 24 Inplanted Sensionics CGM Inplanted Glysense CGM Implanted fluorescent CGM Lasts up to 9 days Implanted in doctor s office MARD ~11.4% Vibe alerts when low or high Adhesive base for transmitter replaced daily Bluetooth LE communication to cell phone Rechargeable battery glysens.com Implanted dual-enzyme CGM Lasts 12 mos or more Implanted in surgeon s office MARD? Vibe alerts when low or high Proprietary receiver Rechargeable battery glysens.com The AP Pathway Artificial Pancreas Projects Basal Threshold Suspend Reactive Predictive Control to Range Control to Target Bi-hormonal fda.gov GuidanceDocuments/UCM25935.pdf 6

Steps to a Better Artificial Pancreas Early AP System Approved More accurate CGM devices More rapid insulins Further refinements in control algorithm (exercise, stress, illness, etc) Improved user interface and connectivity More reliable longer-lasting infusion sets Stable glucagon Dual-hormone systems Medtronic 67G Available April or May 217 Treat to target, proportional integral derivative Enlite 3 MARD: 1.3% No Bluetooth For meal boluses: Manually bolus well before eating Eat mostly low-gi foods Or give larger meal bolus (risk reduced, essentially a Super Bolus) 67G Pivitol Study Bigfoot Biomedical 14 mg/dl A1c lowered by.5% from 7.4% to 6.9% in 124 people 44% reduction in time under 7 mg/dl 4% decline in time under 5 mg/dl 11% decline over 18 mg/dl with 8% more time-in-range (71-18 mg/dl) Asante pump + Dexcom CGM + Smart Phone Milpitas, CA; available late 217 or 218 www.bigfootbiomedical.com Univ of Virginia Type Zero Bionic Pancreas Univ of Virginia Diabetes Assist. Tandem Diabetes or CellNovo pump, Dexcom G5 or G6 $12.7 mil NIH study To market late 217 or 218 Treat to target, model predictive control Developed at Boston Univ. by Ed Damiano, PhD. Insulin only late 217 Insulin + glucagon 218 Treat to target, model predictive control Crowdsource funding at wefunder.com/betabionics/ or sites.bu.edu/bionicpancreas/ donate/ http://www.artificialpancreas.org/ 7

Do It Yourself with OpenAPS Viacyte Encapsulated Pancreas Visit www.openaps.org Assembly is required!!! www.nightscoutfoundation.org Full pancreas response insulin, glucagon, somatostatin. " Pec-Encap Pancreatic endoderm cells encapsulated in an Encaptra drug delivery system. Being revised. " Pec-Direct Direct vascularization of cells, immune suppression required. viacyte.com Questions PI5 on Kindle, i-pad, and Nook $16.99 Slides at www.diabetesnet.com/ diabetes-resources/diabetespresentations Books at www.diabetesnet.com/dmall/ or 8-988-4772 8